Safety and efficacy of Durvalumab with or without Tremelimumab in patients with PD-L1-low/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial - Siu, Lillian L.; Krauß, Jürgen (JAMA oncology, 2019)
Gesehen am 20.09.2019